Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409048 | 1.00 | KMT2A (0.51) | KMT2ACA2CA1MAPTSMN1; SMN2 | |
| SCHEMBL2409042 | 1.00 | KMT2A (0.51) | KMT2ACA2CA1MAPTSMN1; SMN2 | |
| SCHEMBL2409493 | 1.00 | KMT2A (0.51) | KMT2ACA2CA1MAPTSMN1; SMN2 | |
| SCHEMBL2409046 | 1.00 | KMT2A (0.51) | KMT2ACA2CA1MAPTSMN1; SMN2 | |
| SCHEMBL2409487 | 1.00 | KMT2A (0.51) | KMT2ACA2CA1MAPTSMN1; SMN2 | |
| SCHEMBL25896990 | 0.87 | CA1 (0.37) | KMT2ACA2CA1MAPTSMN1; SMN2 | |
| SCHEMBL26045346 | 0.87 | CA1 (0.37) | KMT2ACA2CA1MAPTSMN1; SMN2 | |
| SCHEMBL17909507 | 0.83 | CA1 (0.53) | CA2CA1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL2232451 | 0.83 | CA1 (0.53) | CA2CA1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL2232449 | 0.83 | CA1 (0.53) | CA2CA1MAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| CN-116209438-A | Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors | 锐新医药公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-115916194-A | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115873020-A | RAS inhibitors | 锐新医药公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-4114823-A1 | PROCESSES FOR PRODUCING AMIDE COMPOUNDS, AND THEIR CRYSTALLINE AND SALT FORM | Alphala Co., Ltd. (TW) | 2023-01-11 | — | — | EP | disclosed |
| CN-115052855-A | Preparation method of amide compound, crystal form and salt thereof | 昊运股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-114901366-A | RAS inhibitors | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021178486-A1 | PROCESSES FOR PRODUCING AMIDE COMPOUNDS, AND THEIR CRYSTALLINE AND SALT FORM | ALPHALA CO., LTD. (TW) | 2021-09-10 | — | — | WO | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140275093-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20110212969-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011106632-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275093-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC10, HDAC1 | KMT2A 137/4885CA2 308/4885CA1 310/4885 |
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | KMT2A 3873/4885CA2 3772/4885CA1 4562/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | KMT2A 3685/4885CA2 3819/4885CA1 4685/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | KMT2A 3021/4885CA2 3441/4885CA1 4070/4885 |
| US-20110212969-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC10, HDAC1 | KMT2A 137/4885CA2 308/4885CA1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.